FHTX
NASDAQ HealthcareFoghorn Therapeutics Inc. - Common Stock
Biotechnology
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
๐ Market Data
| Price | $5.07 |
|---|---|
| Volume | 294,270 |
| Market Cap | 297.68M |
| Beta | 2.860 |
| RSI (14-Day) | 63.4 |
| 200-Day MA | $4.85 |
| 50-Day MA | $4.43 |
| 52-Week High | $6.95 |
| 52-Week Low | $3.27 |
| Forward P/E | -4.62 |
| Price / Book | -3.90 |
๐ฏ Investment Strategy Scores
FHTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (96/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find FHTX in your text
Paste any article, transcript, or post โ the tool will extract FHTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.